Clayton Adams, MD
Interventional Pain Medicine · Austin, TXNPI 1699069104
Payments from drug & device makers
Across 935 payments — averaging $23.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$16K
- Boston Scientific$2K
- Biodelivery Sciences International, Inc.$1K
- AbbVie$364
- Nalu Medical, Inc.$352
- Collegium Pharmaceutical, Inc.$269
- plus $2K from 24 others
What the payments were for
- Speaking & faculty fees$1,0005%
- Travel & lodging$6233%
- Food & beverage$20,31493%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 770 | $16,475 |
| Boston Scientific | 35 | $1,794 |
| Biodelivery Sciences International, Inc. | 9 | $1,059 |
| AbbVie(2 entities) | 24 | $364 |
| Nalu Medical, Inc. | 4 | $352 |
| Collegium Pharmaceutical, Inc. | 15 | $269 |
| Medtronic(2 entities) | 8 | $219 |
| Nevro Corp. | 3 | $189 |
| Amgen | 9 | $163 |
| Biohaven Pharmaceutical Holding Company Ltd. | 10 | $141 |
| SPR Therapeutics, Inc | 1 | $138 |
| Novartis | 6 | $100 |
| Arbor Pharmaceuticals, Inc. | 4 | $77 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $73 |
| Pfizer | 4 | $70 |
| Teva Pharmaceuticals USA, Inc. | 4 | $59 |
| GRT US Holding, Inc. | 7 | $46 |
| Saluda Medical Americas, Inc. | 1 | $46 |
| Biohaven Pharmaceuticals, Inc. | 3 | $46 |
| Scilex Pharmaceuticals Inc. | 3 | $44 |
| Redhill Biopharma Inc. | 2 | $32 |
| Argenx US, Inc. | 1 | $30 |
| Forte Bio-pharma LLC | 1 | $25 |
| Upsher-smith Laboratories LLC | 1 | $22 |
| Assertio Therapeutics, Inc. | 1 | $22 |
| Azurity Pharmaceuticals, Inc. | 1 | $20 |
| IBSA Pharma Inc. | 1 | $20 |
| Eisai Inc. | 1 | $17 |
| MDD US Operations, LLC | 1 | $15 |
| Daiichi Sankyo Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- PROCLAIM$2,694
- OCTRODE$1,620
- Proclaim IPG$1,176
- WaveWriter Alpha Prime 16$1,027
- Nalu Neurostimulation System$249
- SPRINT PNS System$138
- Octrode SCS Leads$132
- ETERNA$120
- Proclaim Family of SCS IPGs$120
- ADAPTIVESTIM$120
- GENERAL PAIN MANAGEMENT$114
- Senza Spinal Cord Stimulation System$111
- UBRELVY$106
How this compares
$21,938 in reported general payments places this provider in the 80th percentile of 287 interventional pain medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 1,915 | $59,948 |
| BelbucaBuprenorphine Hcl | 46 | $33,229 |
| OxycontinOxycodone Hcl | 83 | $31,777 |
| Hysingla ErHydrocodone Bitartrate | 55 | $25,820 |
| Xtampza ErOxycodone Myristate | 53 | $24,020 |
| NucyntaTapentadol Hcl | 14 | $15,877 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 578 | $14,141 |
| Buprenorphine | 41 | $13,204 |
| QuliptaAtogepant | 11 | $11,939 |
| Morphine Sulfate ErMorphine Sulfate | 327 | $11,469 |
| Fentanyl | 49 | $8,947 |
| Oxycodone Hcl | 530 | $8,167 |
| ZtlidoLidocaine | 17 | $7,593 |
| Oxymorphone Hcl ErOxymorphone Hcl | 12 | $5,459 |
| Pregabalin | 118 | $4,005 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Collegium Pharmaceutical, Inc.Belbuca, Xtampza Er, Nucynta | $269 | $73,127113 claims |
| AbbVieQulipta | $364 | $11,93911 claims |
| Scilex Pharmaceuticals Inc.Ztlido | $44 | $7,59317 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 287 interventional pain medicine providers in Texas.
Other interventional pain medicine in Austin
- Genaro GutierrezAustin$1.3M
- Brannon FrankAustin$698K
- Anjuli DesaiAustin$82K
- Paul leAustin$27K
- Martin ThaiAustin$23K
- Gabor RaczLubbock$3M
- Pankaj MehtaKilleen$2.2M
- Chad StephensSouthlake$1.1M
- Ioannis SkaribasHouston$979K
- Duane GriffithTyler$730K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.